Oxford, UK – 01 December 2018: Oxford Biomedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis on the longer-term analyses of both the ELIANA and JULIET pivotal trials in children and young adult patients with relapsed or refractory… Read More
Oxford, UK – 23 November 2018: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces the formation of a new digital framework initiative to streamline the production of next-generation medicines. Oxford Biomedica will invest a total of £4 million, supported by… Read More
Oxford, UK – 25 October 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, notes that its partner, Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, has announced the successful dosing of the first patient in… Read More
London, UK – 5 October 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces additional details of its strategic alliance with Orchard Therapeutics, as disclosed in the public filing by Orchard Therapeutics on a Form F-1 Registration Statement ahead of… Read More
Lentiviral vector bioprocessing market expected to grow to $800m by 2026 Oxford BioMedica adds fourth facility in Oxford allowing the Group to target 25% to 30% of global lentiviral vector bioprocessing market (excluding milestones and royalties) Oxford, UK – 13 September 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica”… Read More
Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2018. FINANCIAL HIGHLIGHTSGross income growth of 118% to £36.0 million (H1 2017: £15.7 million) Operating EBITDA… Read More
London, UK – 28 August 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of paediatric and… Read More
Oxford, UK – 6 August 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has entered into a process development collaboration agreement with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations to develop a long-term… Read More
London, UK – 29 June 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of… Read More
~ Conference call for analysts to be held at 2:30pm BST / 9:30am ET (see details below) Oxford, UK– 06 June 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has entered into an exclusive worldwide licensing agreement… Read More
Oxford BioMedica plc (“Oxford BioMedica”, “the Company” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announced on 4 May 2018 a proposed share capital Consolidation of the existing ordinary share capital of the Company. The effect of the proposed Consolidation will be to reduce the number of… Read More